Biogenvs.BioMarin Pharmaceutical
BIIB vs BMRN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Biogen is about 2.3× larger than BioMarin Pharmaceutical by market cap; Biogen trades at the lower P/E (37.2 vs 183.0); year to date, Biogen leads (+23.9% vs +9.5%).
Side by side
| BIIB | BMRN | |
|---|---|---|
| Market cap | $31B | $13.4B |
| Price | $220.77 | $66.12 |
| Today | +1.2% | +1.6% |
| Return YTD | +23.9% | +9.5% |
| Return 1Y | +56.6% | +11.1% |
| P/E | 37.2 | 183.0 |
| P/S | 3.1 | 3.9 |
| P/B | 1.6 | 2.1 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →BioMarin PharmaceuticalBMRN
Rare genetic disorders define the company. It sells enzyme replacement therapies and Voxzogo for dwarfism, and has taken gene therapy into hemophilia.
Full BMRN profile →More BIIB & BMRN comparisons
Other head-to-heads in the Biotech & innovation segment.
See where BIIB and BMRN sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →